1. Home
  2. CHA vs GKOS Comparison

CHA vs GKOS Comparison

Compare CHA & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHA
  • GKOS
  • Stock Information
  • Founded
  • CHA 2017
  • GKOS 1998
  • Country
  • CHA China
  • GKOS United States
  • Employees
  • CHA N/A
  • GKOS N/A
  • Industry
  • CHA
  • GKOS Medical/Dental Instruments
  • Sector
  • CHA
  • GKOS Health Care
  • Exchange
  • CHA NYSE
  • GKOS Nasdaq
  • Market Cap
  • CHA 5.5B
  • GKOS 5.1B
  • IPO Year
  • CHA 2025
  • GKOS 2015
  • Fundamental
  • Price
  • CHA $28.01
  • GKOS $94.31
  • Analyst Decision
  • CHA
  • GKOS Strong Buy
  • Analyst Count
  • CHA 0
  • GKOS 13
  • Target Price
  • CHA N/A
  • GKOS $135.15
  • AVG Volume (30 Days)
  • CHA 1.1M
  • GKOS 914.5K
  • Earning Date
  • CHA 05-30-2025
  • GKOS 04-30-2025
  • Dividend Yield
  • CHA N/A
  • GKOS N/A
  • EPS Growth
  • CHA 186.29
  • GKOS N/A
  • EPS
  • CHA 1.95
  • GKOS N/A
  • Revenue
  • CHA $1,699,604,333.00
  • GKOS $404,523,000.00
  • Revenue This Year
  • CHA N/A
  • GKOS $27.89
  • Revenue Next Year
  • CHA N/A
  • GKOS $27.57
  • P/E Ratio
  • CHA $14.34
  • GKOS N/A
  • Revenue Growth
  • CHA 167.35
  • GKOS 23.92
  • 52 Week Low
  • CHA $27.21
  • GKOS $77.10
  • 52 Week High
  • CHA $41.80
  • GKOS $163.71
  • Technical
  • Relative Strength Index (RSI)
  • CHA N/A
  • GKOS 50.08
  • Support Level
  • CHA N/A
  • GKOS $93.52
  • Resistance Level
  • CHA N/A
  • GKOS $101.57
  • Average True Range (ATR)
  • CHA 0.00
  • GKOS 3.33
  • MACD
  • CHA 0.00
  • GKOS 0.40
  • Stochastic Oscillator
  • CHA 0.00
  • GKOS 42.24

About CHA CHAGEE HOLDINGS LTD SPON ADS EACH R SPON ADS EACH REP 1 CL A

Chagee Holdings Ltd is a premium tea drinks brand. It is engaged in the sales of freshly-made tea drinks, related raw materials, packaging, teahouse equipment and other supplies in China.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: